Advertisement

Archives of Virology

, Volume 161, Issue 7, pp 1899–1906 | Cite as

Prevalence of occult hepatitis C virus infection in Iranian patients with beta thalassemia major

  • Mohammad-Navid Bastani
  • Farah Bokharaei-SalimEmail author
  • Hossein Keyvani
  • Maryam Esghaei
  • Seyed Hamidreza Monavari
  • Mojtaba Ebrahimi
  • Saba Garshasebi
  • Shahin Fakhim
Original Article

Abstract

Occult hepatitis C virus infection (OCI) is a new pathological form of chronic hepatitis virus (HCV) infection characterized by the presence of HCV RNA in liver biopsy and/or peripheral blood mononuclear cell (PBMC) specimens and the absence of HCV RNA and anti-HCV antibodies (Abs) in plasma samples. β-thalassemia major is a hereditary recessive blood disease with deficiency in the hemoglobin beta chain. Thalassemic patients need blood transfusion therapy; repeated blood transfusion increases the risk of viral blood-borne infection. The aim of this study was to determine the prevalence of OCI in Iranian patients with β-thalassemia major. From February 2015 to November 2015, a total of 147 Iranian patients with β-thalassemia major were enrolled in this cross-sectional study. After extraction of viral RNA from the plasma and PBMC samples, HCV genomic RNA in the specimens was amplified by RT-nested PCR using primers from the 5′-UTR. The HCV genotypes of the positive specimens were tested using the RFLP assay. To confirm the HCV genotypes, the 5′-UTR fragment was amplified and cloned into the pJET1.2/blunt cloning vector and then sequenced. Out of 147 patients, 106 (72.1 %) were negative for anti-HCV Abs and HCV RNA. HCV RNA was found in PBMC specimens of six (5.7 %) patients, from a total of 106 patients with undetectable plasma HCV RNA and anti-HCV Abs. Therefore, six out of 106 patients had OCI. HCV genotyping revealed that three patients were infected with HCV subtype 1b, two patients were infected with HCV subtype 3a, and one patient was infected with HCV subtype 1a. These results revealed that Iranian patients with beta-thalassemia major might have OCI. Therefore, it seems that the design of a study to identify this infection in patients with β-thalassemia major would provide valuable information.

Keywords

Iranian Patient Peripheral Blood Mononuclear Cell Sample Blunt Cloning Vector Positive Peripheral Blood Mononuclear Cell Peripheral Blood Mononuclear Cell Specimen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The current study was funded by Research Deputy of Iran University of Medical Sciences, grant number 25379.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict(s) of interest.

Supplementary material

705_2016_2862_MOESM1_ESM.pdf (160 kb)
Supplementary material 1 (PDF 160 kb)

References

  1. 1.
    Laskus T, Operskalski EA, Radkowski M, Wilkinson J, Mack WJ, deGiacomo M et al (2007) Negative-strand hepatitis C virus (HCV) RNA in peripheral blood mononuclear cells from anti-HCV-positive/HIV-infected women. J Infect Dis 195(1):124–133CrossRefPubMedGoogle Scholar
  2. 2.
    Keyvani H, Bokharaei-Salim F, Monavari SH, Esghaei M, Nassiri Toosi M, Fakhim S et al (2013) Occult hepatitis C virus infection in candidates for liver transplant with cryptogenic cirrhosis. Hepat Mon 13(8):e11290CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Galanello R, Origa R (2010) Beta-thalassemia. Orphanet J Rare Dis 5:11CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hamid H, Iqbal R, Khan M, Iftikhar B, Aziz S, Burki F et al (2008) Prevalence of hepatitis C in beta thalassaemic major. Gomal J Med Sci 6(2)Google Scholar
  5. 5.
    Ansar MM, Kooloobandi A (2002) Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. J Viral Hepat 9(5):390–392CrossRefPubMedGoogle Scholar
  6. 6.
    Jafroodi M, Davoudi-Kiakalayeh A, Mohtasham-Amiri Z, Pourfathollah AA, Haghbin A (2015) Trend in prevalence of hepatitis c virus infection among beta-thalassemia major patients: 10 years of experience in Iran. Int J Prev Med 6:89CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Castillo I, Pardo M, Bartolome J, Ortiz-Movilla N, Rodriguez-Inigo E, de Lucas S et al (2004) Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 189(1):7–14CrossRefPubMedGoogle Scholar
  8. 8.
    Vidimliski PD, Nikolov I, Geshkovska NM, Dimovski A, Rostaing L, Sikole A (2014) Review: occult hepatitis C virus infection: still remains a controversy. J Med Virol 86(9):1491–1498CrossRefPubMedGoogle Scholar
  9. 9.
    Saravanan S, Velu V, Kumarasamy N, Shankar EM, Nandakumar S, Murugavel KG et al (2008) The prevalence of hepatitis B virus and hepatitis C virus infection among patients with chronic liver disease in South India. Int J Infect Dis 12(5):513–518CrossRefPubMedGoogle Scholar
  10. 10.
    Sadeghi F, Bokharaei-Salim F, Salehi-Vaziri M, Monavari SH, Alavian SM, Salimi S et al (2014) Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNalpha-2a and ribavirin in Iranian patients with chronic hepatitis C. J Med Virol 86(9):1499–1506CrossRefPubMedGoogle Scholar
  11. 11.
    Bokharaei-Salim F, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Nasseri S (2013) Distribution of hepatitis C virus genotypes among azerbaijani patients in capital city of iran-tehran. Hepat Mon 13(9):e13699CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Schroter M, Zollner B, Schafer P, Laufs R, Feucht HH (2001) Comparison of three HCV genotyping assays: a serological method as a reliable and inexpensive alternative to PCR based assays. J Clin Virol 23(1–2):57–63CrossRefPubMedGoogle Scholar
  13. 13.
    Bokharaei-Salim F, Keyvani H, Monavari SH, Alavian SM, Madjd Z, Toosi MN et al (2011) Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease. J Med Virol 83(6):989–995CrossRefPubMedGoogle Scholar
  14. 14.
    Jahanbakhsh Sefidi F, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F (2013) Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. Hepat Mon 13(1):e7991CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Pohjanpelto P, Lappalainen M, Widell A, Asikainen K, Paunio M (1996) Hepatitis C genotypes in Finland determined by RFLP. Clin Diagn Virol. 7(1):7–16CrossRefPubMedGoogle Scholar
  16. 16.
    Shaker O, Ahmed A, Abdel Satar I, El Ahl H, Shousha W, Doss W (2012) Occult hepatitis B in Egyptian thalassemic children. J Infect Dev Ctries 6(4):340–346CrossRefPubMedGoogle Scholar
  17. 17.
    Taherkhani R, Farshadpour F (2015) Epidemiology of hepatitis C virus in Iran. World J Gastroenterol 21(38):10790–10810CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Carreno V, Bartolome J, Castillo I, Quiroga JA (2012) New perspectives in occult hepatitis C virus infection. World J Gastroenterol 18(23):2887–2894CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Vento S, Cainelli F, Cesario F (2006) Infections and thalassaemia. Lancet Infect Dis 6(4):226–233CrossRefPubMedGoogle Scholar
  20. 20.
    Khodabandehloo M, Roshani D, Sayehmiri K (2013) Prevalence and trend of hepatitis C virus infection among blood donors in Iran: a systematic review and meta-analysis. J Res Med Sci 18(8):674–682PubMedPubMedCentralGoogle Scholar
  21. 21.
    Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR et al (2010) Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis 14(Suppl 3):e113–e116CrossRefPubMedGoogle Scholar
  22. 22.
    Farahani M, Bokharaei-Salim F, Ghane M, Basi A, Meysami P, Keyvani H (2013) Prevalence of occult hepatitis C virus infection in Iranian patients with lymphoproliferative disorders. J Med Virol 85(2):235–240CrossRefPubMedGoogle Scholar
  23. 23.
    Alavian S-M, Adibi P, Zali M-R (2005) Hepatitis C virus in Iran: epidemiology of an emerging infection. Arch Iran Med 8(2):84–90Google Scholar
  24. 24.
    De Marco L, Gillio-Tos A, Fiano V, Ronco G, Krogh V, Palli D et al (2009) Occult HCV infection: an unexpected finding in a population unselected for hepatic disease. PLoS One 4(12):e8128CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernandez N et al (2008) Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 19(12):2288–2292CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Thongsawat S, Maneekarn N, Kuniholm MH, Pantip C, Thungsuputi A, Lumlertkul D et al (2008) Occult hepatitis C virus infection during an outbreak in a hemodialysis unit in Thailand. J Med Virol 80(5):808–815CrossRefPubMedGoogle Scholar
  27. 27.
    Baid-Agrawal S, Schindler R, Reinke P, Staedtler A, Rimpler S, Malik B et al (2014) Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients. J Hepatol 60(5):928–933CrossRefPubMedGoogle Scholar
  28. 28.
    Castillo I, Martinez-Ara J, Olea T, Bartolome J, Madero R, Hernandez E et al (2014) High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies. Kidney Int 86(3):619–624CrossRefPubMedGoogle Scholar
  29. 29.
    Sugden PB, Pham TN, Ratnarajah S, Cameron B, Bull R, White PA et al (2013) Rare occurrence of occult hepatitis C virus in apparently uninfected injecting drug users: a two-centre, masked, case-control study. J Viral Hepat 20(10):725–728CrossRefPubMedGoogle Scholar
  30. 30.
    Zaghloul H, El-Sherbiny W (2010) Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells. Immunol Invest 39(3):284–291CrossRefPubMedGoogle Scholar
  31. 31.
    Idrees M, Lal A, Malik FA, Hussain A, Rehman I, Akbar H et al (2011) Occult hepatitis C virus infection and associated predictive factors: the Pakistan experience. Infect Genet Evol 11(2):442–445CrossRefPubMedGoogle Scholar
  32. 32.
    Comar M, Dal Molin G, D’Agaro P, Croce SL, Tiribelli C, Campello C (2006) HBV, HCV, and TTV detection by in situ polymerase chain reaction could reveal occult infection in hepatocellular carcinoma: comparison with blood markers. J Clin Pathol 59(5):526–529CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    De Marco L, Manzini P, Trevisan M, Gillio-Tos A, Danielle F, Balloco C et al (2012) Prevalence and follow-up of occult HCV infection in an Italian population free of clinically detectable infectious liver disease. PLoS One 7(8):e43541CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Gatserelia L, Sharvadze L, Karchava M, Dolmazashvili E, Tsertsvadze T (2014) Occurrence of occult HCV infection among Hiv infected patients in Georgia. Georgian Med News 226:37–41PubMedGoogle Scholar
  35. 35.
    Eslamifar A, Ramezani A, Ehteram H, Razeghi E, Ahmadi F, Amini M et al (2015) Occult hepatitis C virus infection in Iranian hemodialysis patients. J Nephropathol 4(4):116–120PubMedPubMedCentralGoogle Scholar
  36. 36.
    Richiardi L, De Marco L, Gillio-Tos A, Merletti F, Fiano V, Palli D et al (2010) Persistent infection by HCV and EBV in peripheral blood mononuclear cells and risk of non-Hodgkin’s lymphoma. Cancer Epidemiol 34(6):709–712CrossRefPubMedGoogle Scholar
  37. 37.
    Giannini C, Giannelli F, Zignego AL (2006) Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. Hepatology 43(5):1166–1167 (author reply 7–8) CrossRefPubMedGoogle Scholar
  38. 38.
    Welker MW, Zeuzem S (2009) Occult hepatitis C: how convincing are the current data? Hepatology 49(2):665–675CrossRefPubMedGoogle Scholar
  39. 39.
    Rezaee Zavareh MS, Alavian SM, Karimisari H, Shafiei M, Saiedi Hosseini SY (2014) Occult hepatitis C virus infection in patients with autoimmune hepatitis. Hepat Mon 14(8):e16089CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Wien 2016

Authors and Affiliations

  • Mohammad-Navid Bastani
    • 1
  • Farah Bokharaei-Salim
    • 1
    • 2
    Email author
  • Hossein Keyvani
    • 1
  • Maryam Esghaei
    • 1
  • Seyed Hamidreza Monavari
    • 1
  • Mojtaba Ebrahimi
    • 3
  • Saba Garshasebi
    • 2
  • Shahin Fakhim
    • 4
  1. 1.Department of VirologyIran University of Medical SciencesTehranIslamic Republic of Iran
  2. 2.HIV Laboratory of National Center, Deputy of HealthIran University of Medical SciencesTehranIslamic Republic of Iran
  3. 3.Iranian Blood Transfusion Organization (IBTO), Thalassemia CenterTehranIslamic Republic of Iran
  4. 4.Department of Civil Engineering, Faculty of EngineeringPayame Noor UniversityKarajIslamic Republic of Iran

Personalised recommendations